Sten Fredrikson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6244001/publications.pdf

Version: 2024-02-01

158	6,480	61984	79698
papers	citations	43 h-index	73 g-index

164	164	164	6300
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Picornavirus May Be Linked to Parkinsonâ€™s Disease through Viral Antigen in Dopamine-Containing Neurons of Substantia Nigra. Microorganisms, 2022, 10, 599.	3.6	2
2	Narcolepsy among firstâ€•and secondâ€generation immigrants in Sweden: A study of the total population. Acta Neurologica Scandinavica, 2022, 146, 160-166.	2.1	2
3	Telephone validation of an Urdu translated version of the extended disability severity scale in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 48, 102684.	2.0	6
4	Associations Between Fluctuations in Daytime Sleepiness and Motor and Nonâ€Motor Symptoms in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 44-50.	1.5	7
5	Huntingtonâ€™s disease among immigrant groups and Swedish-born individuals: a cohort study of all adults 18 years of age and older in Sweden. Neurological Sciences, 2021, 42, 3851-3856.	1.9	1
6	Amyotrophic lateral sclerosis (ALS) among immigrant groups and Swedish-born individuals: a cohort study of all adults 18Âyears of age and older in Sweden. Journal of Neurology, 2021, , 1.	3.6	0
7	Multiple sclerosis among firstâ€•and secondâ€generation immigrant groups in Sweden. Acta Neurologica Scandinavica, 2020, 142, 339-349.	2.1	5
8	Multiple sclerosis in Pakistan: Current status and future perspective. Journal of the Neurological Sciences, 2020, 418, 117066.	0.6	8
9	Parkinsonâ€™s Disease Among Immigrant Groups and Swedish-Born Individuals: A Cohort Study of All Adults 50 Years of Age and Older in Sweden. Journal of Parkinson's Disease, 2020, 10, 1133-1141.	2.8	4
10	Epilepsy in immigrants and Swedish-born: A cohort study of all adults 18 years of age and older in Sweden. Seizure: the Journal of the British Epilepsy Association, 2020, 76, 116-122.	2.0	1
11	Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis. Annals of Neurology, 2020, 87, 710-724.	5.3	42
12	RebiQoL: A randomized trial of telemedicine patient support program for health-related quality of life and adherence in people with MS treated with Rebif. PLoS ONE, 2019, 14, e0218453.	2.5	11
13	Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis. American Journal of Neuroradiology, 2019, 40, 1265-1273.	2.4	24
14	A 10-Year Follow-Up of Excessive Daytime Sleepiness in Parkinsonâ€™s Disease. Parkinson's Disease, 2019, 2019, 1-7.	1.1	10
15	Lesion accumulation is predictive of long-term cognitive decline in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 21, 110-116.	2.0	20
16	Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management. European Journal of Neurology, 2018, 25, 739-746.	3.3	12
17	Detection of Leukocortical Lesions in Multiple Sclerosis and Their Association with Physical and Cognitive Impairment: A Comparison of Conventional and Synthetic Phase-Sensitive Inversion Recovery MRI. American Journal of Neuroradiology, 2018, 39, 1995-2000.	2.4	17
18	Survey of diagnostic and treatment practices for multiple sclerosis in Europe. European Journal of Neurology, 2017, 24, 516-522.	3.3	34

#	Article	IF	Citations
19	Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. The Cochrane Library, 2017, 4, CD012200.	2.8	20
20	Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study. American Journal of Neuroradiology, 2017, 38, 1311-1316.	2.4	48
21	Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. CNS Drugs, 2017, 31, 33-50.	5.9	57
22	Clinical Feasibility of Synthetic MRI in Multiple Sclerosis: A Diagnostic and Volumetric Validation Study. American Journal of Neuroradiology, 2016, 37, 1023-1029.	2.4	104
23	A single-group pilot feasibility study of cognitive behavioural therapy in people with multiple sclerosis with depressive symptoms. Disability and Rehabilitation, 2016, 38, 2383-2391.	1.8	7
24	Incidence of Radiologically Isolated Syndrome: A Population-Based Study. American Journal of Neuroradiology, 2016, 37, 1017-1022.	2.4	40
25	A 10-year follow-up of the European multicenter trial of interferon Î²-1b in secondary-progressive multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 533-543.	3.0	24
26	Is excessive daytime sleepiness a separate manifestation in Parkinson's disease?. Acta Neurologica Scandinavica, 2015, 132, 97-104.	2.1	20
27	MRIâ€Defined Corpus Callosal Atrophy in Multiple Sclerosis: A Comparison of Volumetric Measurements, Corpus Callosum Area and Index. Journal of Neuroimaging, 2015, 25, 996-1001.	2.0	40
28	Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study. Multiple Sclerosis Journal, 2015, 21, 1151-1158.	3.0	63
29	Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1116-1121.	1.9	139
30	Health-related quality of life in partners of persons with MS: a longitudinal 10-year perspective. BMJ Open, 2014, 4, e006097.	1.9	5
31	A 10-year follow-up of a population-based study of people with multiple sclerosis in Stockholm, Sweden: Changes in disability and the value of different factors in predicting disability and mortality. Journal of the Neurological Sciences, 2013, 332, 121-127.	0.6	40
32	Reports of Patients and Relatives from the CogniCIS Study about Cognition in Clinically Isolated Syndrome: What Are Our Patients Telling Us?. European Neurology, 2013, 69, 346-351.	1.4	5
33	Radiologically isolated syndrome â€“ incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review. Multiple Sclerosis Journal, 2013, 19, 271-280.	3.0	116
34	Callosal atrophy in multiple sclerosis is related to cognitive speed. Acta Neurologica Scandinavica, 2013, 127, 281-289.	2.1	28
35	People with multiple sclerosis in Denmark who use complementary and alternative medicineâ€”Do subgroups of patients differ?. European Journal of Integrative Medicine, 2013, 5, 365-373.	1.7	4
36	The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nature Reviews Neurology, 2013, 9, 267-276.	10.1	181

#	Article	IF	Citations
37	A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden. Journal of Medical Economics, 2013, 16, 756-762.	2.1	5
38	Interferon Â for secondary progressive multiple sclerosis: a systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 420-426.	1.9	47
39	Radiologically isolated syndrome: an uncommon finding at a university clinic in a high-prevalence region for multiple sclerosis. BMJ Open, 2013, 3, e003531.	1.9	13
40	Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Multiple Sclerosis Journal, 2013, 19, 765-774.	3.0	66
41	Differences between users and non-users of complementary and alternative medicine among people with multiple sclerosis in Denmark: A comparison of descriptive characteristics. Scandinavian Journal of Public Health, 2013, 41, 492-499.	2.3	23
42	Multiple sclerosis in Pakistan: histocompatibility antigen composition and disability. Multiple Sclerosis Journal, 2013, 19, 254-255.	3.0	5
43	Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsingâ€“remitting multiple sclerosis in Sweden. Journal of Medical Economics, 2013, 16, 349-357.	2.1	8
44	Emerging Oral Medications for Multiple Sclerosis. , 2012, , .		0
45	Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Multiple Sclerosis Journal, 2012, 18, 891-898.	3.0	654
46	Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-BarrÃ© syndrome and chronic inflammatory demyelinating polyneuropathy. Acta Neurologica Scandinavica, 2012, 125, 129-135.	2.1	27
47	Cost-Effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients With a First Clinical Event Suggestive of Multiple Sclerosis. Clinical Therapeutics, 2012, 34, 1132-1144.	2.5	13
48	A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images. Neuroradiology, 2010, 52, 109-117.	2.2	28
49	The first case history of multiple sclerosis: Augustus dâ€™EstÃ© (1794â€“1848). Neurological Sciences, 2010, 31, 29-33.	1.9	19
50	Evaluation of multiple sclerosis diagnostic criteria in Suzhou, China Ã¢Â€Â“ risk of under-diagnosis in a low prevalence area. Acta Neurologica Scandinavica, 2010, 121, 24-29.	2.1	9
51	Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health and Quality of Life Outcomes, 2010, 8, 133.	2.4	44
52	"We noticed that suddenly the country has become full of MRI". Policy makers' views on diffusion and use of health technologies in Iran. Health Research Policy and Systems, 2010, 8, 9.	2.8	24
53	CSF immune variables in patients with narcolepsy. Acta Neurologica Scandinavica, 2009, 81, 253-254.	2.1	57
54	Lessons from randomised direct comparative trials. Journal of the Neurological Sciences, 2009, 277, S19-S24.	0.6	11

#	Article	IF	Citations
55	Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 448-454.	3.0	55
56	Diffusion of interferon beta in Iran and its utilization in Tehran. Pharmacoepidemiology and Drug Safety, 2008, 17, 934-941.	1.9	8
57	Cord blood contains cells secreting antibodies to nervous system components. Clinical and Experimental Immunology, 2008, 84, 353-358.	2.6	7
58	The expression of TNF-Î± receptors 1 and 2 on peripheral blood mononuclear cells in chronic inflammatory demyelinating polyneuropathy. Journal of Neuroimmunology, 2008, 200, 129-132.	2.3	6
59	Use of health care services and satisfaction with care in people with multiple sclerosis in Stockholm County: A population-based study. Multiple Sclerosis Journal, 2008, 14, 962-971.	3.0	40
60	How is magnetic resonance imaging used in Iran?. International Journal of Technology Assessment in Health Care, 2008, 24, 452-458.	0.5	13
61	Clinical features of patients with multiple sclerosis from a survey in Shanghai, China. Multiple Sclerosis Journal, 2008, 14, 671-678.	3.0	28
62	Effects of inpatient rehabilitation in multiple sclerosis patients with moderate disability. Advances in Physiotherapy, 2008, 10, 58-65.	0.2	15
63	Diffusion of magnetic resonance imaging in Iran. International Journal of Technology Assessment in Health Care, 2007, 23, 278-285.	0.5	21
64	Multiple sclerosis in Pakistan. Multiple Sclerosis Journal, 2007, 13, 668-669.	3.0	21
65	Selective Decline in Information Processing in Subgroups of Multiple Sclerosis: An 8-Year Longitudinal Study. European Neurology, 2007, 57, 193-202.	1.4	119
66	A caseâ€“control study of Guillainâ€“Barre syndrome in Harbin, China. European Journal of Neurology, 2006, 13, 953-957.	3.3	7
67	Costs and quality of life of multiple sclerosis in Sweden. European Journal of Health Economics, 2006, 7, 75-85.	2.8	63
68	Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 375-380.	1.9	41
69	Cognitive and motor function in people with multiple sclerosis in Stockholm County. Multiple Sclerosis Journal, 2006, 12, 340-353.	3.0	52
70	Health-related quality of life in a population-based sample of people with multiple sclerosis in Stockholm County. Multiple Sclerosis Journal, 2006, 12, 605-612.	3.0	58
71	Activities of daily living and social activities in people with multiple sclerosis in Stockholm County. Clinical Rehabilitation, 2006, 20, 543-551.	2.2	88
72	Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. Multiple Sclerosis Journal, 2004, 10, 5-8.	3.0	24

#	Article	IF	Citations
73	Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens, 2004, 63, 237-247.	1.0	130
74	Cost-utility of interferon Î² 1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. European Journal of Health Economics, 2003, 4, 50-59.	2.8	39
75	Interferon-Î² treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity. British Journal of Clinical Pharmacology, 2003, 56, 337-340.	2.4	6
76	Prospective study of clinical epidemiology of Guillainâ€“BarrÃ© syndrome in Harbin, China. Journal of the Neurological Sciences, 2003, 215, 63-69.	0.6	14
77	Multiple sclerosis in Stockholm County. A pilot study exploring the feasibility of assessment of impairment, disability and handicap by home visits. Clinical Rehabilitation, 2003, 17, 294-303.	2.2	30
78	Elevated Suicide Risk among Patients with Multiple Sclerosis in Sweden. Neuroepidemiology, 2003, 22, 146-152.	2.3	91
79	Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-Î²and IL-10. Clinical and Experimental Immunology, 2002, 124, 306-314.	2.6	37
80	HHV-6 A- or B-specific P41 antigens do not reveal virus variant-specific IgG or IgM responses in human serum. Journal of Medical Virology, 2002, 66, 394-399.	5.0	19
81	Multiple sclerosis in Stockholm County. A pilot study of utilization of health-care resources, patient satisfaction with care and impact on family caregivers. Acta Neurologica Scandinavica, 2002, 106, 241-247.	2.1	16
82	A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis. Genes and Immunity, 2002, 3, 279-285.	4.1	73
83	Distinct pattern of age-specific incidence of Guillain-BarrÃ© syndrome in Harbin, China. Journal of Neurology, 2002, 249, 25-32.	3.6	41
84	Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. European Journal of Neurology, 2001, 8, 27-35.	3.3	155
85	The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis. Genes and Immunity, 2001, 2, 263-268.	4.1	44
86	Linkage analysis suggests a region of importance for multiple sclerosis in 3p14â€“13. Genes and Immunity, 2001, 2, 451-454.	4.1	4
87	COST-UTILITY ANALYSIS OF INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS. International Journal of Technology Assessment in Health Care, 2000, 16, 768-780.	0.5	35
88	Neutralizing and binding anti-interferon-Î² (IFN-Î²) antibodies. A comparison between IFN-Î²-1a and IFN-Î²-1b treatment in multiple sclerosis. European Journal of Neurology, 2000, 7, 27-34.	3.3	67
89	Decreased mRNA expression of TNF-alpha and IL-10 in non-stimulated peripheral blood mononuclear cells in myasthenia gravis. European Journal of Neurology, 2000, 7, 195-202.	3.3	10
90	Clinical epidemiology of Guillainâ€“BarrÃ© syndrome in adults in Sweden 1996â€“97: a prospective study. European Journal of Neurology, 2000, 7, 685-692.	3.3	43

#	Article	IF	Citations
91	Epidemiological surveillance ofGuillain-BarrÃ© syndrome in Sweden,1996-1997. Acta Neurologica Scandinavica, 2000, 101, 104-111.	2.1	15
92	Linkage analysis of a candidate region in Scandinavian sib pairs with multiple sclerosis reveals linkage to chromosome 17q. Genes and Immunity, 2000, 1, 456-459.	4.1	29
93	Multiple sclerosis:. Journal of Neuroimmunology, 2000, 108, 236-243.	2.3	83
94	Multiple Sclerosis: Levels of Interleukin-10-Secreting Blood Mononuclear Cells are Low in Untreated Patients but Augmented During Interferon-beta-1b Treatment. Scandinavian Journal of Immunology, 1999, 49, 554-561.	2.7	67
95	High numbers of perforin mRNA expressing CSF cells in multiple sclerosis patients with gadolinium-enhancing brain MRI lesions. Acta Neurologica Scandinavica, 1999, 100, 18-24.	2.1	11
96	First hospital-admission rate as an epidemidogical indicator for patients with multiple sclerosis in Stockholm, 1984-1993. Acta Neurologica Scandinavica, 1999, 100, 64-68.	2.1	5
97	Association and linkage analysis of candidate chromosomal regions in multiple sclerosis: indication of disease genes in 12q23 and 7ptrâ€“15. European Journal of Human Genetics, 1999, 7, 110-116.	2.8	23
98	Bilateral subdural haematomas following lumbar puncture in three haematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 1999, 24, 1033-1035.	2.4	13
99	Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. Journal of Neuroimmunology, 1999, 99, 82-90.	2.3	91
100	Linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis. Annals of Neurology, 1999, 46, 612-616.	5.3	52
101	Linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis. Annals of Neurology, 1999, 46, 612-616.	5.3	1
102	A New Cell Enzyme-Linked Immunosorbent Assay Demonstrates Gamma Interferon Suppression by Beta Interferon in Multiple Sclerosis. Vaccine Journal, 1999, 6, 415-419.	2.6	12
103	Similar Humoral and Cellular Immunological Reactivities to Human Herpesvirus 6 in Patients with Multiple Sclerosis and Controls. Vaccine Journal, 1999, 6, 545-549.	2.6	57
104	No eidence for increased frequency of autoantibodies during interferon-Î²_{lb}treatment of multiple sclerosis. Acta Neurologica Scandinavica, 1998, 97, 320-323.	2.1	23
105	The B-cell repertoire in myasthenia gravis includes all four acetylcholine receptor subunits. Acta Neurologica Scandinavica, 1998, 98, 422-426.	2.1	4
106	No evidence for elevated numbers of mononuclear cells expressing MCP-1 and RANTES mRNA in blood and CSF in multiple sclerosis. Journal of Neuroimmunology, 1998, 91, 108-112.	2.3	18
107	Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis. European Journal of Neurology, 1998, 5, 265-275.	3.3	21
108	Interleukinâ€12 and Perforin mRNA Expression is Augmented in Blood Mononuclear Cells in Multiple Sclerosis. Scandinavian Journal of Immunology, 1998, 47, 582-590.	2.7	32

#	Article	IF	Citations
109	IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS). Clinical and Experimental Immunology, 1998, 111, 193-197.	2.6	60
110	Linkage and association analysis of genes encoding cytokines and myelin proteins in multiple sclerosis. Journal of Neuroimmunology, 1998, 86, 13-19.	2.3	63
111	Chronic fatigue syndrome differs from fibromyalgia. No evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome. Pain, 1998, 78, 153-155.	4.2	65
112	Soluble CD30 levels in plasma and cerebrospinal fluid in multiple sclerosis, HIV infection and other nervous system diseases. Acta Neurologica Scandinavica, 1997, 95, 99-102.	2.1	4
113	Absence of seven human herpesviruses, including HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis. Acta Neurologica Scandinavica, 1997, 95, 280-283.	2.1	101
114	Multiple sclerosis and amyloid deposits in the white matter of the brain. Acta Neuropathologica, 1997, 93, 205-209.	7.7	4
115	Guillain-BarrÃ© syndrome in South-West Stockholm, 1973â€“1991, 2. Clinical epidemiology. Italian Journal of Neurological Sciences, 1997, 18, 49-53.	0.1	6
116	A zone immunoelectrophoresis assay method for quantification of apolipoprotein D in human cerebrospinal fluid. Journal of Proteomics, 1996, 33, 1-8.	2.4	4
117	Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. Journal of Neuroimmunology, 1996, 64, 63-69.	2.3	80
118	Multiple sclerosis: the proinflammatory cytokines lymphotoxin-Î± and tumour necrosis factor-Î± are upregulated in cerebrospinal fluid mononuclear cells. Journal of Neuroimmunology, 1996, 66, 115-123.	2.3	52
119	Tumor necrosis factor-Î±, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis. Journal of Neuroimmunology, 1996, 71, 191-198.	2.3	47
120	Lyme neuroborreliosis: cerebrospinal fluid contains myelin proteinâ€reactive cells secreting interferonâ€Î³. European Journal of Neurology, 1996, 3, 122-129.	3.3	4
121	Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis. Acta Neurologica Scandinavica, 1996, 94, 31-34.	2.1	37
122	Increased mRNA Expression of IL-10 in Mononuclear Cells in Multiple Sclerosis and Optic Neuritis. Scandinavian Journal of Immunology, 1995, 41, 171-178.	2.7	64
123	Lyme Neuroborreliosis: Evidence for Persistent Up-Regulation of Borrelia Burgdorferi-Reactive Cells Secreting Interferon-gamma. Scandinavian Journal of Immunology, 1995, 42, 694-700.	2.7	27
124	Expression of IFN-Î³, IL-4, and TGF-Î² in multiple sclerosis in relation to HLA-Dw2 phenotype and stage of disease. Multiple Sclerosis Journal, 1995, 1, 173-180.	3.0	19
125	Analysis of CD27 surface expression on T cell subsets in MS patients and control individuals. Journal of Neuroimmunology, 1995, 56, 99-105.	2.3	22
126	Transforming growth factor-Î²1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis. Journal of Neuroimmunology, 1995, 58, 21-35.	2.3	46

#	Article	IF	Citations
127	Guillain-BarrÃ© syndrome in South-West Stockholm, 1973-1991, 1. Quality of registered hospital diagnoses and incidence. Acta Neurologica Scandinavica, 1995, 91, 109-117.	2.1	41
128	Organ-specific autoantigens induce transforming growth factor-Î² mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Annals of Neurology, 1994, 35, 197-203.	5.3	54
129	Î³Î´+ T cells are increased in patients with Parkinson's disease. Journal of the Neurological Sciences, 1994, 121, 39-45.	0.6	103
130	Augmented interferon-Î³, interleukin-4 and transforming growth factor-Î² mRNA expression in blood mononuclear cells in myasthenia gravis. Journal of Neuroimmunology, 1994, 51, 185-192.	2.3	36
131	VÎ´1 gene usage, interleukin-2 receptors and adhesion molecules on Î³Î´+ T cells in inflammatory disease of the nervous system. Journal of Neuroimmunology, 1994, 49, 59-66.	2.3	9
132	The HLA-Dw2 haplotype segregates closely with multiple sclerosis in multiplex families. Journal of Neuroimmunology, 1994, 50, 95-100.	2.3	43
133	Multiple sclerosis: occurrence of myelin basic protein peptide-reactive T cells in healthy family members. Acta Neurologica Scandinavica, 1994, 89, 184-189.	2.1	10
134	Optic neuritis and multiple sclerosis: the T cell repertoires to myelin proteins and MBP peptides change with time. Acta Neurologica Scandinavica, 1994, 90, 10-18.	2.1	12
135	Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurologica Scandinavica, 1994, 90, 160-166.	2.1	111
136	T Cells Recognizing Multiple Peptides of Myelin Basic Protein are Found in Blood and Enriched in Cerebrospinal Fluid in Optic Neuritis and Multiple Sclerosis. Scandinavian Journal of Immunology, 1993, 37, 355-368.	2.7	41
137	Interleukin-2 secreting cells in multiple sclerosis and controls. Journal of the Neurological Sciences, 1993, 120, 99-106.	0.6	23
138	Myasthenia gravis: T and B cell reactivities to the Î²-bungarotoxin binding protein presynaptic membrane receptor. Journal of the Neurological Sciences, 1992, 109, 173-181.	0.6	18
139	Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis. Journal of Neuroimmunology, 1992, 38, 63-73.	2.3	72
140	The T-Cell Repertoire in Myasthenia Gravis Involves Multiple Cholinergic Receptor Epitopes. Scandinavian Journal of Immunology, 1992, 36, 405-414.	2.7	19
141	T cell responses to human recombinant acetylcholine receptor-Î± subunitin myasthenia gravis and controls. European Journal of Immunology, 1992, 22, 1553-1559.	2.9	28
142	CD5+ B cells and CD4â^'8â^' T cells in neuroimmunological diseases. Journal of Neuroimmunology, 1991, 32, 123-132.	2.3	31
143	Interleukin-6 is elevated in plasma in multiple sclerosis. Journal of Neuroimmunology, 1991, 31, 147-153.	2.3	114
144	Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. European Journal of Immunology, 1991, 21, 1461-1468.	2.9	246

#	Article	IF	Citations
145	Cells producing antibodies specific for myelin basic protein region 70â€“89 are predominant in cerebrospinal fluid from patients with multiple sclerosis. European Journal of Immunology, 1991, 21, 2971-2976.	2.9	36
146	The 150-Year Anniversary of Multiple Sclerosis: Does Its Early History Give an Etiological Clue?. Perspectives in Biology and Medicine, 1989, 32, 237-243.	0.5	18
147	Mononuclear Cell Types in Cerebrospinal Fluid and Blood of Patients With Multiple Sclerosis. Archives of Neurology, 1989, 46, 372.	4.5	8
148	Retrovirus in multiple sclerosis. Acta Neurologica Scandinavica, 1989, 80, 467-471.	2.1	4
149	Total, anti-viral, and anti-myelin IgG subclass reactivity in inflammatory diseases of the central nervous system. Journal of Neurology, 1989, 236, 238-242.	3.6	31
150	Bone marrow cells in patients with multiple sclerosis. Journal of Neuroimmunology, 1989, 24, 23-31.	2.3	4
151	Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 7113-7117.	7.1	241
152	CNS-borreliosis selectively affecting central motor neurons. Acta Neurologica Scandinavica, 1988, 78, 181-184.	2.1	34
153	Bone Marrow Cells in Multiple Sclerosis.. Annals of the New York Academy of Sciences, 1988, 540, 282-285.	3.8	3
154	Combination ELISAs for antiviral antibodies in CSF and serum in patients with neurological symptoms and in healthy controls. Journal of Virological Methods, 1988, 19, 169-179.	2.1	18
155	HLA CLASS II GENES IN CHRONIC PROGRESSIVE AND IN RELAPSING/REMITTING MULTIPLE SCLEROSIS. Lancet, The, 1987, 330, 327.	13.7	13
156	Increased reactivity to HTLV-I in inflammatory nervous system diseases. Annals of Neurology, 1987, 22, 67-71.	5.3	22
157	CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurologica Scandinavica, 1987, 75, 352-355.	2.1	45
158	Genomic HLAâ€typing by RFLPâ€analysis using DRÎ² and DQÎ² cDNA probes reveals normal DRâ€DQ linkages in patients with multiple sclerosis. Tissue Antigens, 1987, 30, 135-138.	1.0	10